• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

保守治疗的乳腺癌患者上肢水肿:肥胖是主要预测因素。

Arm edema in conservatively managed breast cancer: obesity is a major predictive factor.

作者信息

Werner R S, McCormick B, Petrek J, Cox L, Cirrincione C, Gray J R, Yahalom J

机构信息

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

出版信息

Radiology. 1991 Jul;180(1):177-84. doi: 10.1148/radiology.180.1.2052688.

DOI:10.1148/radiology.180.1.2052688
PMID:2052688
Abstract

To identify risk factors in the development of arm edema (AE) after conservative management of breast cancer, the authors prospectively measured differences in upper and lower arm circumference in 282 patients with stage I or II breast cancer who received radiation. AE was defined as a difference of 2.5 cm or more in either measurement between treated and untreated arms. Median follow-up was 37 months (range, 7-109 months). The crude frequency of AE overall was 19.5% (55 patients). In 21 patients (7.4%) AE was transient; 34 patients (12.1%) had persistent AE, which is the focus of this article. The 5-year actuarial incidence of persistent AE was 16%. The crude risk of persistent severe AE was 3.9%. Various factors were examined for their ability to enable prediction of AE. Treatment-related factors did not significantly enable prediction of AE, whereas factors related to patient size, such as body mass index, were strongly associated with both the frequency and severity of AE.

摘要

为了确定乳腺癌保守治疗后发生手臂水肿(AE)的风险因素,作者前瞻性地测量了282例接受放疗的I期或II期乳腺癌患者上臂和下臂周长的差异。AE定义为治疗侧与未治疗侧手臂的任何一项测量差值达2.5厘米或以上。中位随访时间为37个月(范围7 - 109个月)。AE的总体粗发生率为19.5%(55例患者)。21例患者(7.4%)的AE为短暂性;34例患者(12.1%)有持续性AE,这是本文的重点。持续性AE的5年精算发病率为16%。持续性严重AE的粗风险为3.9%。研究了各种因素预测AE的能力。与治疗相关的因素不能显著预测AE,而与患者体型相关的因素,如体重指数,与AE的发生率和严重程度均密切相关。

相似文献

1
Arm edema in conservatively managed breast cancer: obesity is a major predictive factor.保守治疗的乳腺癌患者上肢水肿:肥胖是主要预测因素。
Radiology. 1991 Jul;180(1):177-84. doi: 10.1148/radiology.180.1.2052688.
2
Early-stage breast cancer: arm edema after wide excision and breast irradiation.早期乳腺癌:广泛切除及乳房放疗后的手臂水肿。
Radiology. 1996 Jan;198(1):279-83. doi: 10.1148/radiology.198.1.8539394.
3
Obesity is a risk factor for developing postoperative lymphedema in breast cancer patients.肥胖是乳腺癌患者术后发生淋巴水肿的一个风险因素。
Breast J. 2010 Jan-Feb;16(1):48-54. doi: 10.1111/j.1524-4741.2009.00855.x. Epub 2009 Nov 2.
4
Predictors of lymphedema in patients with breast cancer undergoing axillary lymph node dissection in Hong Kong.香港接受腋窝淋巴结清扫术的乳腺癌患者发生淋巴水肿的预测因素。
Nurs Res. 2008 Nov-Dec;57(6):416-25. doi: 10.1097/NNR.0b013e31818c3de2.
5
Management of the axilla in operable breast cancer treated by breast conservation: a randomized clinical trial. Edinburgh Breast Unit.保乳治疗的可手术乳腺癌腋窝处理:一项随机临床试验。爱丁堡乳腺科
Br J Surg. 2000 Feb;87(2):163-9. doi: 10.1046/j.1365-2168.2000.01345.x.
6
Early self-reported impairments in arm functioning of primary breast cancer patients predict late side effects of axillary lymph node dissection: results from a population-based cohort study.原发性乳腺癌患者早期自我报告的手臂功能损伤可预测腋窝淋巴结清扫术的晚期副作用:一项基于人群的队列研究结果
Breast Cancer Res Treat. 2006 Dec;100(3):285-92. doi: 10.1007/s10549-006-9247-3. Epub 2006 May 20.
7
Lymphedema of the arm and breast in irradiated breast cancer patients: risks in an era of dramatically changing axillary surgery.接受放疗的乳腺癌患者手臂和乳房的淋巴水肿:腋窝手术发生巨大变化时代的风险
Breast J. 2004 Sep-Oct;10(5):405-11. doi: 10.1111/j.1075-122X.2004.21411.x.
8
Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer.I期或II期乳腺癌前哨淋巴结活检或腋窝淋巴结清扫术后1年与治疗相关的上肢并发症
Ann Surg Oncol. 2004 Nov;11(11):1018-24. doi: 10.1245/ASO.2004.03.512. Epub 2004 Oct 15.
9
Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer.腋窝清扫术后乳腺癌患者上肢淋巴水肿风险预测的列线图。
Ann Surg Oncol. 2012 Aug;19(8):2580-9. doi: 10.1245/s10434-012-2290-x. Epub 2012 Mar 7.
10
Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.局部晚期非炎性乳腺癌的联合化疗与术前放疗:120例患者的最新结果
Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1062-73. doi: 10.1016/j.ijrobp.2003.12.034.

引用本文的文献

1
Educational Review: Management of Lymphedema-Approaches, Evidence for Surgical and Nonsurgical Interventions.教育综述:淋巴水肿的管理——手术及非手术干预方法与证据
Ann Surg Oncol. 2025 May 20. doi: 10.1245/s10434-025-17463-x.
2
Metformin Use and Risk of Breast Cancer-Related Lymphedema: A Retrospective Analysis.二甲双胍的使用与乳腺癌相关淋巴水肿风险:一项回顾性分析。
J Am Coll Surg. 2025 May 5. doi: 10.1097/XCS.0000000000001434.
3
Bariatric Lymphedema One-Stage Operative Management (BLOOM).减重手术相关淋巴水肿一期手术治疗(BLOOM)。
Obes Surg. 2025 May;35(5):1860-1863. doi: 10.1007/s11695-025-07847-z. Epub 2025 Apr 8.
4
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may reduce the risk of developing cancer-related lymphedema following axillary lymph node dissection (ALND).胰高血糖素样肽-1受体激动剂(GLP-1 RAs)可能会降低腋窝淋巴结清扫术(ALND)后发生癌症相关淋巴水肿的风险。
Front Pharmacol. 2024 Sep 4;15:1457363. doi: 10.3389/fphar.2024.1457363. eCollection 2024.
5
A comparative evaluation of the efficacy of complete decongestive therapy in the treatment of unilateral breast cancer-related lymphedema with and without metabolic syndrome.比较分析完整消肿疗法治疗伴或不伴代谢综合征的单侧乳腺癌相关性淋巴水肿的疗效。
Support Care Cancer. 2024 Jun 29;32(7):473. doi: 10.1007/s00520-024-08676-z.
6
GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report.胰高血糖素样肽-1受体激动剂作为乳腺癌相关淋巴水肿的有效治疗方法:一例报告
Front Oncol. 2024 Apr 18;14:1392375. doi: 10.3389/fonc.2024.1392375. eCollection 2024.
7
The effect of therapeutic exercise in the prevention of lymphoedema secondary to breast cancer: a systematic review.治疗性运动对预防乳腺癌继发淋巴水肿的作用:一项系统评价。
Arch Med Sci. 2020 Dec 3;19(6):1684-1692. doi: 10.5114/aoms.2020.101435. eCollection 2023.
8
The prevention and treatment of breast cancer- related lymphedema: A review.乳腺癌相关淋巴水肿的防治:综述
Front Oncol. 2022 Dec 6;12:1062472. doi: 10.3389/fonc.2022.1062472. eCollection 2022.
9
Lymphedema and Obesity.淋巴水肿与肥胖症。
Cold Spring Harb Perspect Med. 2022 May 27;12(5):a041176. doi: 10.1101/cshperspect.a041176.
10
A retrospective analysis of commonly prescribed medications and the risk of developing breast cancer related lymphedema.常用处方药与患乳腺癌相关淋巴水肿风险的回顾性分析。
Clin Res Trials. 2020 Feb;6(1). doi: 10.15761/crt.1000293. Epub 2020 Feb 28.